Sacituzumab Tirumotecan (MK-2870) in Patients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-Based Combination Therapy
Sacituzumab Tirumotecan (MK-2870) in Patients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-Based Combination Therapy
Not yet recruiting · NCT07720258 · Registry updated 2026-07-22Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Sacituzumab Tirumotecan (MK-2870) in Patients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-Based Combination Therapy | Advanced Small Bowel Adenocarcinoma | Not yet recruiting | Phase 2 | 2026-07-22 | NCT07720258 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| National Cancer Center, Japan | 16 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Aichi Cancer Center Hospital | Nagoya | Japan | 6 |
| Hiroshima University Hospital | Hiroshima | Japan | 13 |
| Kyushu University Hospital | Fukuoka | Japan | 20 |
| National Cancer Center Hospital | Tokyo | Japan | 20 |
| Osaka Medical and Pharmaceutical University Hospital | Takatsuki | Japan | 2 |